TABLE II.
Patient no. | FEV1 (% predicted) | FEV1/FVC ratio (%) | DLCO (% predict) | Complications | CT findings |
---|---|---|---|---|---|
1 | 113 | 108 | 70 | ITP | Nodular opacities Ground-glass opacity Mediastinal lymphadenopathy |
2 | 88 | 76 | 58 | ITP AIHA |
Nodular opacities |
3 | 61 (before) 62 (after) |
98 | 51 | PNA Enteropathy |
Nodular opacities Mediastinal lymphadenopathy Bronchiectasis |
4 | 71 | 75 | 109 | PNA ITP |
Nodular opacities Mediastinal lymphadenopathy |
5 | 71 (before) 72 (after) |
104 | 77 | PNA ITP |
Nodular opacities Ground-glass opacity Mediastinal lymphadenopathy |
6 | 91 | 107 | NA | PNA ITP |
Nodular opacities Mediastinal lymphadenopathy Bronchiectasis |
Pulmonary function testing was conducted before biopsy. One patient, patient 6, did not have DLCO measured as part of preoperative evaluation. CT findings are provided retrospectively as diagnosed by attending radiologists.
AIHA, Autoimmune hemolytic anemia; FVC, forced vital capacity; ITP, immune thrombocytopenic purpura; PNA, pneumonia.